贝达药业:BPI-572270是一款分子胶抑制剂,目前该项目正推进提交临床研究申请(IND)准备工作

每日经济新闻
Nov 06, 2025

每经AI快讯,有投资者在投资者互动平台提问:公司的分子胶和降解剂项目何时可以申报临床?贝达药业(300558.SZ)11月6日在投资者互动平台表示,BPI-572270是一款分子胶抑制剂,目前该项目正在推进提交临床研究申请(IND)的准备工作。CFT8919片是一种具有口服生物利用度的变构 BiDAC 降解剂,CFT8919项目目前在临床Ⅰ期研究中。(文章来源:每日经济新闻) 海量资讯、精准...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10